Midostaurin (PKC412) for Locally Advanced Rectal Cancer
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study combines midostaurin (PKC412) with radiation and a standard chemotherapy drug call
5-Fluorouracil (5-FU) for subjects with advanced rectal cancer. Midostaurin is a type of
kinase inhibitor which works by blocking proteins associated with cancer cell growth.
Previous studies also suggest that midostaurin may help increase the effectiveness of
radiation therapy. In this research we are looking for the highest dose of midostaurin that
can be given safely in combination with standard chemoradiation.